Table 3: Nonpharmacologic management and prevention of hypertensive disorders in pregnancy / CMAJ

Nonpharmacologic management and prevention of hypertensive disorders in pregnancy

Table 3: Meta-analyses of RCTs of nonpharmacologic therapy (plasma volume expansion, fish oil supplementation or low-dose ASA therapy) in the treatment or prevention of gestational hypertension and associated outcomes*

Interventions Outcome Total sample size No. of RCTs OR (and 95% CI)

Plasma volume expansion v. no expansion⁸⁴ Cesarean section 42   2   2.04  (0.59-7.02)

Perinatal death 32   1   5.70  (0.32-...)

Fish oil supplementation v. placebo⁸⁵ Hypertension 5 135   2   0.95  (0.83-1.09)

Proteinuric pre-eclampsia 5 135   2   0.68  (0.53-0.88)†

Preterm birth 5 550   2   0.79  (0.69-0.90)†

Prophylactic low-dose ASA therapy v. placebo⁸⁶ Proteinuric pre-eclampsia 15 133   17   0.75  (0.67-0.84)†

Perinatal death 15 477   18   0.97  (0.79-1.19)

*ASA = acetylsalicylic acid.
†Statistically significant.

[Return to text]

| CMAJ October 1, 1997 (vol 157, no 7) / JAMC le 1er octobre 1997 (vol 157, no 7) |

CMA Webspinners / Les fileurs du Web de l'AMC

Table 3: Meta-analyses of RCTs of nonpharmacologic therapy (plasma volume expansion, fish oil supplementation or low-dose ASA therapy) in the treatment or prevention of gestational hypertension and associated outcomes*
Interventions	Outcome	Total sample size	No. of RCTs	OR (and 95% CI)
Plasma volume expansion v. no expansion⁸⁴	Cesarean section	42	2	2.04 (0.59-7.02)
Plasma volume expansion v. no expansion⁸⁴	Perinatal death	32	1	5.70 (0.32-...)
Fish oil supplementation v. placebo⁸⁵	Hypertension	5 135	2	0.95 (0.83-1.09)
	Proteinuric pre-eclampsia	5 135	2	0.68 (0.53-0.88)†
	Preterm birth	5 550	2	0.79 (0.69-0.90)†
Prophylactic low-dose ASA therapy v. placebo⁸⁶	Proteinuric pre-eclampsia	15 133	17	0.75 (0.67-0.84)†
Prophylactic low-dose ASA therapy v. placebo⁸⁶	Perinatal death	15 477	18	0.97 (0.79-1.19)
*ASA = acetylsalicylic acid. †Statistically significant.